Navigation Links
Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
Date:12/4/2008

Company Introduces New Trade Name Onrigin(TM) for Laromustine

NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today made several announcements related to events in connection with the 50th American Society of Hematology Annual Meeting at the Moscone Center in San Francisco from December 6-9, 2008.

Vion Poster Presentation

The Company announced that it would present survival data for its lead anticancer product laromustine in a poster presentation.

    Title:      "Survival After Complete Response to Treatment with
                  Laromustine (Cloretazine(R)) in Elderly Patients with Poor
                  Risk Acute
                 Myelogenous Leukemia"
    Date:        Saturday, December 6
    Time:        9:30 a.m. to 7:30 p.m. (authors present 5:30-7:30 p.m.)
    Location:    Moscone Center Hall A, Board I-45

New Trade Name for Laromustine

Vion will introduce Onrigin(TM) as the new trade name for laromustine at the Meeting, replacing Cloretazine(R) (VNP40101M).

Vion Co-Sponsors Seminar on Acute Myelogenous Leukemia in Elderly Patients

The Company is co-sponsoring a seminar at the Meeting, in conjunction with MGI Pharmaceuticals and the Geriatric Oncology Consortium, entitled "Treating AML/MDS in the Elderly: New Solutions for a Long-Standing Problem." The seminar will take place in Rooms 3009, 3011, 3022 and 3024 on Friday, December 5 from 12:30 p.m. to 4:30 p.m. at the Moscone Center West.

Other Posters Related to Laromustine and Triapine(R)

The Company announced that additional posters presented by investigators would be made on laromustine and Triapine(R), its second anticancer agent in
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...stCall/ -- BioSpecifics Technologies Corp. (Nasdaq...first-in-class collagenase-based products, today a...er ended September 30, 2009. ,, "We were extre...A,s Arthritis Advisory Committee unanimously recom...(TM) for the treatment of Dupuytren,s disease, and...
(Date:11/5/2009)...FirstCall/ -- Wound Management Technologies, Inc.,...a Letter of Intent to purchase all healthcare-rela...TC Bulletin Board: VHGI). The deal provides for VH...00 shares of WNDM and a royalty agreement for reve... being acquired from VHGI. WNDM closed at $2.00 ...
(Date:11/5/2009)...rstCall/ -- WaferGen Biosystems, Inc. (OTC Bulleti...e-art genetic analysis systems, today announced th...,s Scientific Advisory Board. His career has been...lecular diagnostics for cancer detection and other...onal biology systems for several biotechnology com...
(Date:11/5/2009)...ewswire-Asia-FirstCall/ -- BMP Sunstone,Corporatio...") today announced,that the Company plans to relea... November 9, 2009, after the market closes. ,...00 pm ET on November 9, 2009,to discuss third quar...y,dialing 1-888-713-4211 or 1-617-213-4864 for int...
Breaking Biology Technology:BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4BMP Sunstone to Report Third Quarter 2009 Financial Results 2
...rch 25 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex:...fourth quarter and year ended December 31, 2008. ,...ich we advanced a new business model focused on lo...gs. We achieved important milestones with our new ...vironment, we were unable to attract financing on ...
..., March 25 Insmed Inc. (Nasdaq: INSM ), a devel...ticals, today announced that on Monday, March 23, ... suspension of the rules requiring a minimum $1 cl...m market value of publicly held shares (MVPHS). T..., July 17, 2009, and the original rules will be re...
...h 25 /PRNewswire-FirstCall/ - Oncolytics Biotech I... announced the completion of patient enrolment in ...r effects of intravenous administration of REOLYSI...n patients with advanced cancers including breast,...e Dr. Johann de Bono of The Royal Marsden NHS Foun...
Other Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:11/3/2009)..., , LAKE ALFRED, FLLaser labeling of fruit and ...a low-energy carbon dioxide laser beam is used to ...liminating the need for common sticker-type labels...riety of fruits and vegetables and is being used i...s. It has been been approved in Asia, South Africa...
(Date:11/3/2009)..., ,, WEST LAFAYETTE, Ind. - Chief executi...erpaid by about 129 times their "ideal salaries" i...lysis proposed by a Purdue University researcher t... most pressing economic and corporate governance i...ages for CEOs," said Venkat Venkatasubramanian, a ...
(Date:11/3/2009)..., , FORT COLLINS, COConsumer interest in new an...y factors including the growth of the "local foods...read reports touting its numerous health benefits,...increasing throughout the U.S. , While most groc... garlic (which is most often imported), varieties ...
Breaking Biology News(10 mins):Laser etching safe alternative for labeling grapefruit 2New theory on fairness in economics targets CEO pay 2New theory on fairness in economics targets CEO pay 3New theory on fairness in economics targets CEO pay 4Sustainably grown garlic 2Sustainably grown garlic 3superDimension Launches Second Generation iLogic 28TM 29Electromagnetic Navigation Bronchoscopy System to Detect and Diagnose Lung Cancer 5915 1superDimension Launches Second Generation iLogic 28TM 29Electromagnetic Navigation Bronchoscopy System to Detect and Diagnose Lung Cancer 5915 2superDimension Launches Second Generation iLogic 28TM 29Electromagnetic Navigation Bronchoscopy System to Detect and Diagnose Lung Cancer 5915 3Dr Julian Henley MD Presents BioMatrix Lift 5911 1Dr Julian Henley MD Presents BioMatrix Lift 5911 2Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies 5907 1Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies 5907 2
...t spring, the Vanderbilt greenhouse held more memb... known to exist in the wild., This unusual bounty ...ifer Ellis, a doctoral student in the biological s...of Professor David E. McCauley., The species is ca...cillatus. It was discovered in 1892 in Tennessee b...
...lfill the molecular requirements for sensing the m...und in retinal neurons of migratory birds (Mourits...tigating what parts of a migratory birds brain are...showed that the cryptochrome-containing neurons in...sen et al., PNAS, 2005; Liedvogel et al., EJN, 200...
... biologist and world-renowned expert on bird speci...ting into a recently published book, Speciation in...evolution at Chicago, evaluates the contributions ...speciation, and the roles of geographical isolatio...e discusses how nearly 10,000 bird species origina...
Other Biology News:Student study bolsters case for adding a rare sunflower to the endangered species list 2University biologist publishes book on bird speciation 2
Rabbit Anti-D-TYROSINE CONJUGATE Polyclonal Antibody, Unconjugated from AbD Serotec
Mouse Anti-Duck IgY Light Chain Monoclonal Antibody, Unconjugated, Clone 14A3 from AbD Serotec
Mouse Anti-NEUROFILAMENTS 140+160 KD Monoclonal Antibody, Unconjugated, Clone BIO-46H from AbD Serotec
Rat Anti-Rat RT1Au (Class I Polymorphic) Monoclonal Antibody, Unconjugated from AbD Serotec
Biology Products: